261 related articles for article (PubMed ID: 30993885)
21. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
[TBL] [Abstract][Full Text] [Related]
22. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
23. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract][Full Text] [Related]
24. EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells.
Zheng M; Cao MX; Luo XJ; Li L; Wang K; Wang SS; Wang HF; Tang YJ; Tang YL; Liang XH
J Cell Mol Med; 2019 Oct; 23(10):6942-6954. PubMed ID: 31368152
[TBL] [Abstract][Full Text] [Related]
25. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
26. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
27. LncRNA SRA mediates cell migration, invasion, and progression of ovarian cancer via NOTCH signaling and epithelial-mesenchymal transition.
Kim LK; Park SA; Yang Y; Kim YT; Heo TH; Kim HJ
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34402503
[TBL] [Abstract][Full Text] [Related]
28. REX1 promotes EMT-induced cell metastasis by activating the JAK2/STAT3-signaling pathway by targeting SOCS1 in cervical cancer.
Zeng YT; Liu XF; Yang WT; Zheng PS
Oncogene; 2019 Oct; 38(43):6940-6957. PubMed ID: 31409905
[TBL] [Abstract][Full Text] [Related]
29. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Park SA; Kim LK; Park HM; Kim HJ; Heo TH
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
[TBL] [Abstract][Full Text] [Related]
31. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
32. Suppression of tongue squamous cell carcinoma growth by inhibition of Jagged1 in vitro and in vivo.
Zhang TH; Liu HC; Liang YJ; Liang LZ; Zheng GS; Huang HZ; Wu JN; Liao GQ
J Oral Pathol Med; 2013 Apr; 42(4):322-31. PubMed ID: 23157415
[TBL] [Abstract][Full Text] [Related]
33. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
[TBL] [Abstract][Full Text] [Related]
34. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
[TBL] [Abstract][Full Text] [Related]
35. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
[TBL] [Abstract][Full Text] [Related]
36. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition.
Amoroso MR; Matassa DS; Agliarulo I; Avolio R; Lu H; Sisinni L; Lettini G; Gabra H; Landriscina M; Esposito F
Cell Death Dis; 2016 Dec; 7(12):e2522. PubMed ID: 27977010
[TBL] [Abstract][Full Text] [Related]
37. Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo.
Lu HY; Zu YX; Jiang XW; Sun XT; Liu TY; Li RL; Wu Q; Zhang YS; Zhao QC
Pharmacol Res; 2019 Oct; 148():104406. PubMed ID: 31442576
[TBL] [Abstract][Full Text] [Related]
38. STAT3 regulates hypoxia-induced epithelial mesenchymal transition in oesophageal squamous cell cancer.
Cui Y; Li YY; Li J; Zhang HY; Wang F; Bai X; Li SS
Oncol Rep; 2016 Jul; 36(1):108-16. PubMed ID: 27220595
[TBL] [Abstract][Full Text] [Related]
39. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.
Sheng WJ; Jiang H; Wu DL; Zheng JH
Braz J Med Biol Res; 2013 Aug; 46(8):650-8. PubMed ID: 23969971
[TBL] [Abstract][Full Text] [Related]
40. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition.
Liu H; Ren G; Wang T; Chen Y; Gong C; Bai Y; Wang B; Qi H; Shen J; Zhu L; Qian C; Lai M; Shao J
Carcinogenesis; 2015 Apr; 36(4):459-68. PubMed ID: 25750173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
